EVORPACEPT | Protein | ovarian cancer | Leukocyte surface antigen CD47 inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | classic Hodgkin lymphoma | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
EVORPACEPT | Protein | non-Hodgkins lymphoma | Leukocyte surface antigen CD47 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | acute myeloid leukemia | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |
MAGROLIMAB | Antibody | acute myeloid leukemia | Leukocyte surface antigen CD47 inhibitor | 1.0 | Terminated | ClinicalTrials |
MAGROLIMAB | Antibody | brain cancer | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | metastatic colorectal cancer | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | myelodysplastic syndrome | Leukocyte surface antigen CD47 inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | ovarian cancer | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |
MAGROLIMAB | Antibody | multiple myeloma | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | urinary bladder cancer | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | colorectal carcinoma | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |
EVORPACEPT | Protein | acute myeloid leukemia | Leukocyte surface antigen CD47 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
EVORPACEPT | Protein | metastatic colorectal cancer | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
EVORPACEPT | Protein | cancer | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | acute myeloid leukemia | Leukocyte surface antigen CD47 inhibitor | 3.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | triple-negative breast cancer | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
EVORPACEPT | Protein | myelodysplastic syndrome | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
EVORPACEPT | Protein | head and neck squamous cell carcinoma | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | non-Hodgkins lymphoma | Leukocyte surface antigen CD47 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | neoplasm | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
EVORPACEPT | Protein | metastatic malignant neoplasm | Leukocyte surface antigen CD47 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | diffuse large B-cell lymphoma | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |
MAGROLIMAB | Antibody | neoplasm | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |
MAGROLIMAB | Antibody | mycosis fungoides | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | lymphoid neoplasm | Leukocyte surface antigen CD47 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | urothelial carcinoma | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | Sezary's disease | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | acute myeloid leukemia | Leukocyte surface antigen CD47 inhibitor | 1.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | head and neck squamous cell carcinoma | Leukocyte surface antigen CD47 inhibitor | 2.0 | Recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | cancer | Leukocyte surface antigen CD47 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
MAGROLIMAB | Antibody | myelodysplastic syndrome | Leukocyte surface antigen CD47 inhibitor | 1.0 | Completed | ClinicalTrials |